Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Abbott's Q3 revenue slightly beats estimates, reaffirms adjusted EPS guidance

By Reuters News


Overview

  • Healthcare firm's Q3 revenue rose 14.5%, slightly beating analyst expectations

  • Adjusted EPS for Q3 met analyst expectations

  • Company expanded portfolio with key new product approvals in diabetes and cancer diagnostics


Outlook

  • Abbott reaffirms full-year 2026 adjusted diluted EPS guidance at $5.50 to $5.55

  • Company expects full-year 2026 comparable sales growth of about 6.0%

  • Abbott projects Q4 2026 adjusted diluted EPS of $1.62 to $1.67


Result Drivers

  • BALANCED GROWTH - Co said strong Q3 results reflected balanced growth across its portfolio, with contributions from multiple businesses

  • DIAGNOSTICS ACQUISITION IMPACT - Growth in diagnostics segment was driven by acquisition of Exact Sciences and increased sales of Cologuard


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Slight Beat*

$13.01 bln

$13 bln (24 Analysts)

Q3 Adjusted EPS

Meet

$1.42

$1.42 (23 Analysts)

Q3 EPS

$0.53

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Abbott Laboratories is $120.50, about 17.6% above its October 20 closing price of $102.45

  • The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • Oct 21 - Abbott to separate global nutrition business

  • Oct 21 - Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

  • Oct 21 - Danaher Q3 adjusted EPS beats, FY guidance raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.